Ignite Creation Date:
2025-12-25 @ 2:00 AM
Ignite Modification Date:
2025-12-27 @ 11:49 PM
Study NCT ID:
NCT00045994
Status:
COMPLETED
Last Update Posted:
2009-07-29
First Post:
2002-09-17
Is NOT Gene Therapy:
True
Has Adverse Events:
False
Brief Title:
The SILVER Study: Systolic Hypertension Interaction With Left Ventricular Remodeling
Sponsor:
Synvista Therapeutics, Inc
Organization:
Study Overview
Official Title:
Systolic and Pulse Pressure Hemodynamic Improvement By Restoring Elasticity: The SILVER Study
Status:
COMPLETED
Status Verified Date:
2007-08
Last Known Status:
None
Delayed Posting:
No
If Stopped, Why?:
Not Stopped
Has Expanded Access:
No
If Expanded Access, NCT#:
N/A
Has Expanded Access, NCT# Status:
N/A
Acronym:
None
Brief Summary:
The purpose of this study is to evaluate the safety and efficacy of ALT-711 in the treatment of isolated systolic hypertension in a formal study in patients with left ventricular hypertrophy. Eligible patients will be randomized to double-blind treatment once daily for 6 months with oral ALT-711 (210 mg) or placebo.
Detailed Description:
None
Study Oversight
Has Oversight DMC:
Is a FDA Regulated Drug?:
Is a FDA Regulated Device?:
Is an Unapproved Device?:
Is a PPSD?:
Is a US Export?:
Is an FDA AA801 Violation?: